You are here

Article info

Article menu
Download PDFPDF
Commentaries
Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?

Authors

  1. Correspondence to Gregory J Gores, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA; gores.gregory{at}mayo.edu
View Full Text

Citation

Rizvi S, Yang JD, Gores GJ
Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?
Gut 2017;66:4-5.

Publication history

  • Received July 28, 2016
  • Revised August 3, 2016
  • Accepted August 4, 2016
  • First published September 1, 2016.
Online issue publication 
July 07, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/